JP MORGAN/CALL/MODERNA/150/0.1/17.01.25 Share Price

Warrant

DE000JL2JML4

Real-time Bid/Ask 18:25:16 05/07/2024 BST
0.9 EUR / 0.92 EUR -8.08% Intraday chart for JP MORGAN/CALL/MODERNA/150/0.1/17.01.25
Current month+3.12%
1 month-56.00%
Date Price Change
05/07/24 0.89 -10.10%
04/07/24 0.99 +11.24%
03/07/24 0.89 -4.30%
02/07/24 0.93 +2.20%
01/07/24 0.91 -5.21%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 06:00 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MODERNA, INC.
Issuer J.P. Morgan
WKN JL2JML
ISINDE000JL2JML4
Date issued 19/04/2023
Strike 150 $
Maturity 17/01/2025 (196 Days)
Parity 10 : 1
Emission price 3.91
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.91
Lowest since issue 0.33
Delta0.37x
Omega 4.351
Premium37.43x
Gearing11.81x
Moneyness 0.7754
Difference Strike 33.07 $
Difference Strike %+22.05%
Spread 0.02
Spread %2.17%
Theoretical value 0.9000
Implied Volatility 56.42 %
Total Loss Probability 77.49 %
Intrinsic value 0.000000
Present value 0.9000
Break even 159.74 €
Theta-0.03x
Vega0.03x
Rho0.02x

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116 USD
Average target price
145.9 USD
Spread / Average Target
+25.79%
Consensus